Literature DB >> 30997488

MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.

Ramesh S Yadava1, Yun K Kim1, Mahua Mandal1, Karunasai Mahadevan1, Jordan T Gladman1, Qing Yu1, Mani S Mahadevan1.   

Abstract

Myotonic dystrophy type 1 (DM1) is caused by an expanded (CTG)n tract in the 3'UTR of the DM protein kinase (DMPK) gene. The RNA transcripts produced from the expanded allele sequester or alter the function of RNA-binding proteins (MBNL1, CUGBP1, etc.). The sequestration of MBNL1 results in RNA-splicing defects that contribute to disease. Overexpression of MBNL1 in skeletal muscle has been shown to rescue some of the DM1 features in a mouse model and has been proposed as a therapeutic strategy for DM1. Here, we sought to confirm if overexpression of MBNL1 rescues the phenotypes in a different mouse model of RNA toxicity. Using an inducible mouse model of RNA toxicity in which expression of the mutant DMPK 3'UTR results in RNA foci formation, MBNL1 sequestration, splicing defects, myotonia and cardiac conduction defects, we find that MBNL1 overexpression did not rescue skeletal muscle function nor beneficially affect cardiac conduction. Surprisingly, MBNL1 overexpression also did not rescue myotonia, though variable rescue of Clcn1 splicing and other splicing defects was seen. Additionally, contrary to the previous study, we found evidence for increased muscle histopathology with MBNL1 overexpression. Overall, we did not find evidence for beneficial effects from overexpression of MBNL1 as a means to correct RNA toxicity mediated by mRNAs containing an expanded DMPK 3'UTR.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30997488      PMCID: PMC6606845          DOI: 10.1093/hmg/ddz065

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  35 in total

1.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

2.  Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Qing Yu; Sadguna Balijepalli; Carla D Frenzel-McCardell; T David Bourne; Lawrence H Phillips
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

3.  Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease.

Authors:  Ranjan Batra; Konstantinos Charizanis; Mini Manchanda; Apoorva Mohan; Moyi Li; Dustin J Finn; Marianne Goodwin; Chaolin Zhang; Krzysztof Sobczak; Charles A Thornton; Maurice S Swanson
Journal:  Mol Cell       Date:  2014-09-25       Impact factor: 17.970

4.  Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity.

Authors:  Yun Kyoung Kim; Mahua Mandal; Ramesh S Yadava; Luc Paillard; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2013-09-02       Impact factor: 6.150

5.  Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy.

Authors:  Frédérique Rau; Fernande Freyermuth; Charlotte Fugier; Jean-Philippe Villemin; Marie-Christine Fischer; Bernard Jost; Doulaye Dembele; Geneviève Gourdon; Annie Nicole; Denis Duboc; Karim Wahbi; John W Day; Harutoshi Fujimura; Masanori P Takahashi; Didier Auboeuf; Natacha Dreumont; Denis Furling; Nicolas Charlet-Berguerand
Journal:  Nat Struct Mol Biol       Date:  2011-06-19       Impact factor: 15.369

6.  TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.

Authors:  Ramesh S Yadava; Erin P Foff; Qing Yu; Jordan T Gladman; Yun K Kim; Kirti S Bhatt; Charles A Thornton; Timothy S Zheng; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2014-12-11       Impact factor: 6.150

7.  Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Authors:  Thurman M Wheeler; Krzysztof Sobczak; John D Lueck; Robert J Osborne; Xiaoyan Lin; Robert T Dirksen; Charles A Thornton
Journal:  Science       Date:  2009-07-17       Impact factor: 47.728

8.  A muscleblind knockout model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Karen A Johnstone; Ami Mankodi; Codrin Lungu; Charles A Thornton; Douglas Esson; Adrian M Timmers; William W Hauswirth; Maurice S Swanson
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

9.  Development of an AP-FRET based analysis for characterizing RNA-protein interactions in myotonic dystrophy (DM1).

Authors:  Shagufta Rehman; Jordan T Gladman; Ammasi Periasamy; Yuansheng Sun; Mani S Mahadevan
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

10.  MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response.

Authors:  Jennifer Davis; Nathan Salomonis; Natasha Ghearing; Suh-Chin J Lin; Jennifer Q Kwong; Apoorva Mohan; Maurice S Swanson; Jeffery D Molkentin
Journal:  Nat Commun       Date:  2015-12-16       Impact factor: 14.919

View more
  11 in total

1.  Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.

Authors:  Tara E Crawford Parks; Kristen A Marcellus; Christine Péladeau; Bernard J Jasmin; Aymeric Ravel-Chapuis
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

2.  Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats.

Authors:  Ludovic Arandel; Magdalena Matloka; Arnaud F Klein; Frédérique Rau; Alain Sureau; Michel Ney; Aurélien Cordier; Maria Kondili; Micaela Polay-Espinoza; Naira Naouar; Arnaud Ferry; Mégane Lemaitre; Séverine Begard; Morvane Colin; Chloé Lamarre; Hélène Tran; Luc Buée; Joëlle Marie; Nicolas Sergeant; Denis Furling
Journal:  Nat Biomed Eng       Date:  2022-02-10       Impact factor: 25.671

3.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 4.  AAV-based gene therapies for the muscular dystrophies.

Authors:  Julie M Crudele; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 5.  Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules.

Authors:  Kaalak Reddy; Jana R Jenquin; John D Cleary; J Andrew Berglund
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 6.208

6.  Myotonic dystrophy type 2: the 2020 update.

Authors:  Giovanni Meola
Journal:  Acta Myol       Date:  2020-12-01

7.  Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy.

Authors:  Ashish N Rao; Hannah M Campbell; Xiangnan Guan; Tarah A Word; Xander Ht Wehrens; Zheng Xia; Thomas A Cooper
Journal:  JCI Insight       Date:  2021-03-08

8.  Modeling muscle regeneration in RNA toxicity mice.

Authors:  Ramesh S Yadava; Mahua Mandal; Jack M Giese; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

Review 9.  Myotonic Dystrophies: A Genetic Overview.

Authors:  Payam Soltanzadeh
Journal:  Genes (Basel)       Date:  2022-02-17       Impact factor: 4.096

Review 10.  TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease.

Authors:  Michael P Fautsch; Eric D Wieben; Keith H Baratz; Nihar Bhattacharyya; Amanda N Sadan; Nathaniel J Hafford-Tear; Stephen J Tuft; Alice E Davidson
Journal:  Prog Retin Eye Res       Date:  2020-07-28       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.